During pregnancy, hypertriglyceridemia is associated with adverse pregnancy outcomes, including gestational hypertension, preeclampsia, gestational diabetes mellitus, large for gestational age (LGA), and preterm delivery. However, whether lifestyle intervention for hypertriglyceridemia during pregnancy improves pregnancy outcomes remains unknown. Therefore, we will conduct a randomized controlled trial to investigate this issue. At a tertiary medical center, we will enroll 70 pregnant women in this prospective, open-label, randomized controlled, pilot study comparing the effect of lifestyle intervention for hypertriglyceridemia versus control between Mar 2020 and Mar 2022. Pregnant women recruited will be randomized into two groups. The intervention group will receive lifestyle intervention; whereas the control group will receive regular surveillance only. Only intervention group will have diet education and exercise goal. They will go to dietitian OPD twice at GA 30-31+6 and 33-34+6 for Mediterranean diet education. As for exercise, participants in intervention group are asked to at least take 10000 steps 3 days a week. Diet modification and exercise intervention will persistent until delivery. The primary end point is the change of biomarkers of preeclampsia and macrosomia, including maternal blood PlGF and sFLT1, and cord blood c-peptide, leptin, IGF-1, IGF-2, IGF-BP1 and IGF-BP3. The secondary end points include the change of frequency of adverse pregnancy outcomes, including individual outcome and the composite outcome, such as gestational hypertension, preeclampsia, preterm delivery, and large for gestational age (defined as birth weight ≥ 90th percentile), change of maternal body weight, change of maternal blood pressure, which is defined as 3 mm-Hg, change of maternal HOMA2-IR, change of maternal plasma triglyceride level and other lipid profile (total cholesterol, HDL, and LDL), echography finding of fetus, neonatal birth weight, change of glucose, and lipid profile (total cholesterol, HDL, LDL, and TG) of fetus cord blood, placental expression of preeclampsia (PlGF, sFLT1) and growth factors (IGF-1, 2, BP1 and BP3).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
70
The intervention group will receive diet education and be given exercise suggestion.
National Taiwan University Hospital
Taipei, Taiwan
Change of biomarkers of preeclampsia
including maternal blood PlGF (pg/mL) and sFLT1 (pg/mL)
Time frame: Through study completion, an average of 2 year
Change of biomarkers of macrosomia
such as cord blood c-peptide (μg/L)
Time frame: Through study completion, an average of 2 year
Change of biomarkers of macrosomia
such as cord blood leptin (ng/mL)
Time frame: Through study completion, an average of 2 year
Change of biomarkers of macrosomia
such as cord blood IGF-1 (ng/mL), IGF-2 (ng/mL)
Time frame: Through study completion, an average of 2 year
Change of biomarkers of macrosomia
such as cord blood IGF-BP1 (μg/mL), and IGF-BP3 (μg/mL)
Time frame: Through study completion, an average of 2 year
Change of frequency of adverse pregnancy outcomes, including individual outcome and the composite outcome
such as gestational hypertension, preeclampsia, preterm delivery, and large for gestational age
Time frame: Through study completion, an average of 2 year
Change of maternal body weight
Maternal body weight change (kilograms)
Time frame: Through study completion, an average of 2 year
Change of maternal plasma triglyceride level (mg/dL) and other lipid profile (total cholesterol, HDL, and LDL)
Other lipid profile including total cholesterol (mg/dL), HDL (mg/dL), and LDL (mg/dL)
Time frame: Through study completion, an average of 2 year
Change of maternal blood pressure
which is defined as 3 mm-Hg
Time frame: Through study completion, an average of 2 year
Change of maternal homeostatic model assessment 2 insulin resistance indexes (HOMA2-IR)
Maternal HOMA2-IR change. The higher level of HOMA2-IR means the higher risk for insulin resistance.
Time frame: Through study completion, an average of 2 year
Change of glucose level of fetus cord blood
Change of glucose level (mg/dL) of fetus cord blood
Time frame: Through study completion, an average of 2 year
Change of lipid profile of fetus cord blood
including TG (mg/dL), total cholesterol (mg/dL), HDL (mg/dL), and LDL (mg/dL)
Time frame: Through study completion, an average of 2 year
Echography finding of fetus
including biparietal diameter (mm), femur length (mm), head circumference (mm), and abdominal circumference (mm)
Time frame: Through study completion, an average of 2 year
Echography finding of fetus
including estimated fetal weight (gm)
Time frame: Through study completion, an average of 2 year
Neonatal birth weight
Neonatal birth weight (grams)
Time frame: Through study completion, an average of 2 year
Placental protein expression (immunohistochemistry or western blot) of preeclampsia biomarkers
including PlGF and sFLT1
Time frame: Through study completion, an average of 2 year
Placental protein expression (immunohistochemistry or western blot) of growth factors
including IGF-1, IGF-2, IGF-BP1, and IGF-BP3
Time frame: Through study completion, an average of 2 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.